Phase I study of sapanisertib (CB ‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors

ConclusionThe combination of sapanisertib and ziv-aflibercept was generally tolerable and demonstrated anti-tumor activity in heavily pre-treated patients with advanced malignancies.

Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel Karp, Vivek Subbiah, Jordi Rodon Ahnert, Sarina A. Piha ‐Paul, John Wright, Senait N. Fessahaye, Fengying Ouyang, Bulent Yilmaz, Funda Meric‐Bernstam, Aung Naing Tags: RESEARCH ARTICLE Source Type: research